一分钟看懂
这是一项关于ALK Positive Malignancies的IV 期研究，登记的药物或干预包括ceritinib，当前状态为研究进行中，已停止招募。登记地点显示中国广州、长春、北京有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
ceritinib · IV 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Novartis Investigative Site · 广州
- Novartis Investigative Site · 长春
- Novartis Investigative Site · 北京
- Novartis Investigative Site · 广州
公开的入选条件
- * Patient is currently receiving treatment with ceritinib within a Novartis-sponsored study which has fulfilled the requirements for the primary objective and, in the opinion of the Investigator, would benefit from continued treatment.
- * Patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.
- * Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures.
- * Written informed consent obtained prior to enrolling in the roll-over study and receiving study medication. If consent cannot be expressed in writing, it must be formally documented and witnessed via an independent trusted witness.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT02584933；登记信息更新于 2026-09-17。